07 Jul, 2023 Findings From Open-Label Extension Study and Qualitative Patient Interview Study of GIVLAARI® (givosiran) Presented at European Association for the Study of the Liver (EASL) Congress 2023
body
At the European Association for the Study of the Liver (EASL) Congress 2023, we presented results from a Phase 1/2, 48-month, open-label extension study and a qualitative patient interview study of givosiran.
Sardh, et al. “Final Results from a Phase 1/2, 48-Month, Open-Label Extension Study of Givosiran in Patients with Acute Intermittent Porphyria
Lombardelli, et al. “Patient Experience with Acute Hepatic Porphyria before and after long-term givosiran treatment: a qualitative interview study”
